Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography
Open Access
- 14 March 2012
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 97 (8), 1173-1180
- https://doi.org/10.3324/haematol.2011.055343
Abstract
Background Thrombin, the final enzyme of blood coagulation, is a multifunctional serine protease also involved in the progression of cancer. Tumor cells may activate blood coagulation proteases through the expression of procoagulant activities. However, specific information about the thrombin generation potential of malignant tissues is lacking. In this study we applied a single global coagulation test, the calibrated automated thrombogram assay, to characterize the specific procoagulant phenotypes of different tumor cells. Design and Methods Malignant hematologic cells (i.e. NB4, HEL, and K562) or solid tumor cells (i.e. MCF-7 breast cancer and H69 small cell lung cells) were selected for the study. The calibrated automated thrombo-gram assay was performed in normal plasma and in plasma samples selectively deficient in factor VII, XII, IX or X, in the absence or presence of a specific anti-tissue factor antibody. Furthermore, cell tissue factor levels were characterized by measuring antigen, activity and mRNA expression. Results In normal plasma, NB4 induced the highest thrombin generation, followed by MCF-7, H69, HEL, and K562 cells. The anti-tissue factor antibody, as well as deficiencies of factors VII, IX and XII affected the thrombin generation potential of malignant cells to different degrees, allowing differentiation of the two different pathways of blood clotting activation – by tissue factor or contact activation. The thrombin generation capacity of NB4 and MCF-7 cells was tissue factor-dependent, as it was highly sensitive to inhibition by anti-tissue factor antibody and factor VII deficiency, while the thrombin generation capacity of H69, HEL and K562 was contact activation-dependent, as no thrombin was generated by these cells in factor XII-deficient plasma. Conclusions This study demonstrates that the calibrated automated thrombogram assay is capable of quantifying, characterizing, and comparing the thrombin generation capacity of different tumor cells. This provides a useful tool for understanding the key factors determining the global pro-coagulant profile of tumors, which is important for addressing specific targeted therapy for the prevention of thrombosis and for cancer.Keywords
This publication has 33 references indexed in Scilit:
- Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleedingBlood, 2011
- Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survivalPatient Related Outcome Measures, 2011
- PML/RARα fusion protein transactivates the tissue factor promoter through a GAGC-containing element without direct DNA associationProceedings of the National Academy of Sciences of the United States of America, 2010
- Detection of endogenous tissue factor levels in plasma using the calibrated automated thrombogram assayThrombosis Research, 2010
- Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogramThrombosis and Haemostasis, 2009
- Monitoring thrombin generation: Is addition of corn trypsin inhibitor needed?Thrombosis and Haemostasis, 2009
- High rate of unprovoked recurrent venous thrombosis is associated with high thrombin‐generating potential in a prospective cohort studyJournal of Thrombosis and Haemostasis, 2008
- Hypercoagulability in patients with haematological neoplasia: No apparent initiation by tissue factorThrombosis and Haemostasis, 2008
- Management of Thrombohemorrhagic Syndromes (THS) in Hematologic MalignanciesHematology-American Society Hematology Education Program, 2007
- Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16‐year periodBritish Journal of Haematology, 1997